Sectoral Asset Management Inc acquired a new stake in Immune Design Corp (NASDAQ:IMDZ) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 168,300 shares of the biotechnology company’s stock, valued at approximately $1,641,000. Sectoral Asset Management Inc owned approximately 0.66% of Immune Design Corp as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the company. Victory Capital Management Inc. lifted its holdings in shares of Immune Design Corp by 2.1% during the 2nd quarter. Victory Capital Management Inc. now owns 1,977,564 shares of the biotechnology company’s stock worth $19,281,000 after acquiring an additional 40,010 shares during the period. Franklin Resources Inc. increased its stake in Immune Design Corp by 2.7% in the second quarter. Franklin Resources Inc. now owns 760,253 shares of the biotechnology company’s stock valued at $7,412,000 after acquiring an additional 20,000 shares during the period. JPMorgan Chase & Co. increased its stake in Immune Design Corp by 118.7% in the second quarter. JPMorgan Chase & Co. now owns 530,702 shares of the biotechnology company’s stock valued at $5,175,000 after acquiring an additional 288,009 shares during the period. Vanguard Group Inc. increased its stake in Immune Design Corp by 37.9% in the second quarter. Vanguard Group Inc. now owns 524,999 shares of the biotechnology company’s stock valued at $5,118,000 after acquiring an additional 144,408 shares during the period. Finally, FMR LLC increased its stake in Immune Design Corp by 0.4% in the first quarter. FMR LLC now owns 445,152 shares of the biotechnology company’s stock valued at $3,027,000 after acquiring an additional 1,699 shares during the period. Institutional investors own 51.46% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Sectoral Asset Management Inc Takes Position in Immune Design Corp (IMDZ)” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/02/sectoral-asset-management-inc-takes-position-in-immune-design-corp-imdz.html.

In other Immune Design Corp news, Director Lewis W. Coleman acquired 12,000 shares of Immune Design Corp stock in a transaction that occurred on Tuesday, July 11th. The shares were acquired at an average cost of $9.05 per share, with a total value of $108,600.00. Following the completion of the purchase, the director now directly owns 40,000 shares of the company’s stock, valued at approximately $362,000. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Leo Guthart acquired 10,000 shares of Immune Design Corp stock in a transaction that occurred on Monday, September 18th. The stock was acquired at an average cost of $9.70 per share, for a total transaction of $97,000.00. The disclosure for this purchase can be found here. Insiders have bought a total of 40,000 shares of company stock valued at $369,760 in the last three months. 20.70% of the stock is owned by insiders.

Several research analysts recently issued reports on the stock. Cowen and Company reissued a “buy” rating on shares of Immune Design Corp in a research report on Tuesday, June 6th. ValuEngine raised Immune Design Corp from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. Jefferies Group LLC reissued a “buy” rating and issued a $18.00 target price on shares of Immune Design Corp in a report on Wednesday, June 28th. Zacks Investment Research upgraded Immune Design Corp from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a research report on Tuesday, July 18th. Finally, BidaskClub lowered Immune Design Corp from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 5th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $16.33.

Immune Design Corp (NASDAQ:IMDZ) traded up 3.38% during mid-day trading on Monday, hitting $10.70. 32,194 shares of the stock traded hands. Immune Design Corp has a 52 week low of $4.50 and a 52 week high of $13.05. The firm’s market cap is $274.12 million. The firm’s 50-day moving average price is $9.58 and its 200-day moving average price is $8.01.

Immune Design Corp (NASDAQ:IMDZ) last issued its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.65) by $0.11. Immune Design Corp had a negative return on equity of 70.03% and a negative net margin of 1,899.31%. The company had revenue of $0.73 million for the quarter, compared to analyst estimates of $1.50 million. On average, equities analysts forecast that Immune Design Corp will post ($2.34) earnings per share for the current fiscal year.

Immune Design Corp Profile

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Want to see what other hedge funds are holding IMDZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immune Design Corp (NASDAQ:IMDZ).

Institutional Ownership by Quarter for Immune Design Corp (NASDAQ:IMDZ)

Receive News & Stock Ratings for Immune Design Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp and related stocks with our FREE daily email newsletter.